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THE physiological relationship between the breast and the ovary has long
been recognised, and as knowledge of this subject has advanced, it has been
applied with increasing benefit to the treatment of advanced carcinoma of the
breast.
Since the first suggestion by Schinzinger at the Surgical Congress in Germany
in 1889 (Schinzinger, 1889) and the first work by Beatson published in 1896,
bilateral o6phorectomy has been tried as an auxiliary method of treatment of
breast cancer. It has been found of value in younger women. With the advent
of X-rays the same effect was brought about by ovarian irradiation (Foveau de
Courmelles, 1926; Ahlbom, 1930).
On the experimental side, the work of Lathrop and Loeb (1916), Loeb (1919)
and Murray (1928) demonstrated the part played by the ovary in the production
of mammary tumours, while Lacassagne (1932) showed that, in certain circum-
stances, mammary carcinomata could be induced by the injection of oestrogenic
substances.
Interest in the problem was further stimulated by the work of Huggins and
Hodges (1941) on the treatment of carcinoma of the prostate by castration and
stilboestrol.
It was logical that the next step in the management of advanced breast
cancer in women should be the use of androgens. Testosterone propionate was
tried with success by Ulirich (1939) and by many later workers.
The treatment ofwomen suffering from breast cancer with one ofthe oestrogen
preparations was apparently illogical, although Zondek (1936) had put forward
the suggestion in 1936. He pointed out that such treatment would bring about
an inhibition ofthe gonadotrophic and growth hormones ofthe anterior pituitary,
and that this, in turn, would produce a " medical castration " and possibly
growth restraint in the tumour.
The next mention in the literature of work of this nature was a symposium
published in June, 1944 (Ellis et al., 1944). The work appears to have been
started independently in various centres as a result of the growing interest in
the relationship between malignant disease and sex hormones. The results
amply proved the value of the oestrogens.
Type of case receiving hormone treatment.
Since 1940 various types of hormone therapy have been used in this Depart-
ment. Such treatment was given to patients who were beyond the aid ofsurgeryRORMONE THERAPY OF ADVANCED BREAST CANCER3
and radiotherapy or who had recurred following orthodox methods of treatment.
In these recurrent cases sufficient time had been allowed to elapse, so that previous
treatment did not influence the results obtained from hormone therapy.
The present series of 656 cases includes patients treated by ovarian irradia-
tion, by surgical castration accompanied by the administration of testosterone
propionate, by various oestrogen preparations (stilboestrol dipropionate, dienoes-
trol, triphenylchlorethylene and ethinyl oestradiol), by ethisterone and by testo-
sterone propionate alone. It also includes a group treated by irradiation of the
pituitary.
Assessment of response.
Assessment ofresponse to the various methods oftreatment was based entirely
on the observed regression of tumour tissue, and improvement in general health
alone was disregarded because such drugs as stilboestrol and testosterone are
known to produce this effect in patients not suffering from malignant disease.
Spontaneous regression of tumours has occasionally been reported (Ewing
1940). They are rare, however, and in over 4000 cases of breast cancer observed
in this Department no spontaneous regression has so far been noted.
The survival rate will be mentioned in the groups of cases to be considered
and, although it seems that life can be prolonged with hormone treatment, no
attempt is made to claim success on this account alone.
The responses were graded as follows:
A. Good response.-There was complete disappearance ofsoft tissue metastases
or radiological evidence of new bone formation in skeletal metastases.
B. Fair response.-There was regression of soft tissue metastases without
complete disappearance, or relief of pain in skeletal metastases.
c. No response.-There was steady progression of the disease.
These three groups, A, B and c, applied to the series treated by ovarian or
pituitary irradiation. Further types of response were noted where hormones
were administered:
D. Adverse response.-The course of the disease appeared to be accelerated.
E. Withdrawal response.-No response was noted during administration ofs
the hormone, but a beneficial effect was produced after the drug had been stopped.
This effect has been noted by others (Farrow, 1944). It may be due to a delayed
response and the point would require further investigation.
Patients Treated by Ovarian Irradiation.
Treatment by ovarian irradiation was begun in May, 1940, and the results
for all patients treated up to June, 1950, have now been assessed.
The technique of treatment has varied slightly over the years, but the aim
was to deliver to the ovaries a dose of about 700 to 800r over a period of one
week. Where the patient lived some distance away, ovarian irradiation was
carried out in a single treatment.
Women of all ages were treated to determine the effect in the different age-
groups. Amongst younger women, the dose was sufficient to bring about a
cessation of menstruation in all cases.
From a consideration of Table I it will be seen that about 20 per cent of all
patients showed a favourable response.
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It will be noted too that the average survival rate after treatment by ovarian
irradiation was longer in the groups showing a good response. This has to be
interpreted carefully because (a) there were many individual exceptions, and
(b) the natural course of the disease is very variable. The difference between
the average survival in groups A and c is so great, however, that even bearing
these qualifying facts in mind, there seems to be no doubt that life can be pro-
longed on occasions by ovarian irradiation.
TABLEI. Re8ults following Ovarian Irradiation.
Total number of cases = 175.
Response. Numbers. Average Averago Percentage
survival/mths. age/yrs. premenopausal.
A. Good . . 17 (9 7%) . 36*2 . 43-1 . 94'1
B. Fair . . 19 (10.9%) . 19*2 . 44.1 94.7
c. None . . 139 (79.4%) . 101 . 49.7 . 48 2
Total . . 175 (100.0%)
As a general rule the best response occurred in women who had not reached
the menopause. Indeed, if premenopausal patients are considered as a separate
group, it is found that approximately 32 per cent showed a response of some
degree.
Each case was carefully tabulated according to the response shown and
according to the histological type of tumour, but no correlation between the
two could be found. All histological types of tumour showed a good response
on occasions.
An attempt was also made to correlate the degree of response with the site
of the metastases, but, here again, no correlation was found. Good responses
were seen in all types of metastases, skin nodules, glands, pulmonary and skeletal
metastases. In 3 patients with osteolytic bone metastases there was radiological
evidence of new bone formation. In 4 a pleural effusion disappeared and in
4 it diminished in amount. One patient showed regression of orbital metastases.
A short account is given of 2 of the patients showing a good response:
Case No. 26,101, Mrs. E. T-.-This patient was first seen on 27.vii.46
when she was 39 years ofage and about 4 months pregnant. She had a carcinoma
ofthe left breast and widespread osteolytic skeletal metastases. She was treated
by simple mastectomy and palliative X-ray therapy to the region ofthe acetabula.
Two months later (15.ix. 46) a film of the pelvis (Fig. 1) showed that there was
still very extensive metastatic involvement of the acetabular regions, and on
this account a caesarean section was performed on 11.x. 46. Fig. 2 shows the
appearance of the pelvis on 29.x.46. Following this she had ovarian irradiation
but the whole pelvis was not irradiated. New bone formation occurred in parts
of the skeleton beyond the treated area. Fig. 3 illustrates the remarkable
response that had occurred in the pelvis by 14.iv.47. Her general health
improved immensely and shebecamepain-free, but later her condition deteriorated
and she died on 3.vii.47.
Case No. 17,361, Mrs. C. S-.-This case illustrates the remarkable reduction
that may occur in a pleural effusion. She was originally treated by simple
mastectomy and X-ray therapy in 1943 for a Stage I carcinoma breast when
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she was 38. In November, 1945, she developed a right-sided pleural effusion
as shown in Fig. 4. She received ovarian irradiation and the effusion gradually
diminished in amount. Fig. 5 illustrates the findings on 9.x.46. After this
her general condition became poorer and she died in February, 1948.
Patients Treated by Surgical Castration and Testosterone.
In 1941 a small group of patients was treated by surgical castration, accom-
panied by the administration of testosterone. This was done in an attempt to
find out why there were some failures with ovarian irradiation. It was thought
that ovarian function might recover to some extent after irradiation and that
the effect of o6phorectomy would be more lasting.
Nine patients with advanced breast carcinoma were treated in this manner
byo6phorectomy, followed bydailyintramuscular injections of25 mg. testosterone
propionate for periods up to 3 months.
Only one patient showed a slight response. She was a premenopausal woman
of 40 with an inoperable breast carcinoma and bone metastases. The primary
tumour became smaller and the glands disappeared temporarily, but no effect
was noted on the skeletal metastases.
Patients Treated by Oestrogen Therapy.
In the latter part of 1942 it was decided to investigate the value of oestrogens
in advanced breast carcinoma, and since that time the following oestrogens
have been tried: stilboestrol dipropionate, dienoestrol, triphenylchlorethylene
and ethinyl oestradiol. The drugs were given to women of all ages.
Stilboestrol dipropionate.
The dose used in the majority of patients was 5 mg. twice a day. This level
of dosage produced only slight gastro-intestinal upset as a rule, and appeared
to be adequate for the production of a good response. In a few patients where
a gastro-intestinal upset was troublesome the dose was reduced to 2-5 mg., 1 mg.
or even 0 5 mg. twice a day.
In patients with a pleural effusion, 5 mg. twice a day sometimes caused suffi-
cient water retention to increase the pleural effusion and add to the patient's
dyspnoea. It was remarkable to find in a few such patients that doses as small
as 0'5 mg. twice or thrice a day were effective in causing a marked reduction or
even disappearance of the effusion.
The drug was given for an initial period of 6 to 8 weeks and then on alternate
months. Administration was continued indefinitely where a good response was
obtained, even although in some cases the patient became clinically free from
disease. This intermittent form of dosage seemed to prolong the good effect,
and also minimised endometrial hyperplasia and the risk of withdrawal menor-
rhagia. Slight vaginal bleeding or discharge occurred intermittently in most
patients.
The incidence of toxic symptoms was not unduly high. The number of
patients having no symptoms attributable to the hormone while taking stilboestrol
was 122, while many ofthe remainder had symptoms which did not inconvenience
them greatly, the most common being nausea and vomiting at the commencement
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of treatment. Many complained of frequency of micturition and incontinence.
Only 8 showed complete intolerance of the drug when given at a lower dosage.
It can be seen from a consideration ofTable II that there was quite a gratifying
response-approximately 30 per cent showing some degree of improvement.
The relation between response and the time of occurrence of the menopause
is as striking as in the group treated by ovarian irradiation, only the reverse
obtains here-the best results are seen after the menopause. There is also an
exceptionally high proportion ofadverse responses among premenopausal women.
This is not a rigid rule, however, as there were adverse responses in older women
(the oldest was over 70) and there were fair responses in young women.
TABLE II.---Results following Treatment with Stilboestrol Dipropionate.
Total number of cases = 322.
Response. Numbers. Average Average Percentage
survival/mths. age/yrs. premenopausal.
A. Good . . 33 (103%/) . 30*5 . 66*3 . 0
B. Fair . . 65 (20.2%) . 19*9 . 62.9 . 9 2
c. None . . 183 (56-8%) . 91 . 57 9 . 17-5
D. Adverse . . 33 (10.3%) * 6-3 . 54.7 . 33-3
E. Withdrawal . 8 (2.4%) . 27X3 3 581 . 12- 5
Total . . 322 (1000%)
Again, as a general rule, those who showed a good response survived longer,
although there were several notable exceptions.
As in the group treated by ovarian irradiation, no correlation was found
here between response and the histological type of the tumour.
In general, where a good response occurred, all metastases showed improve-
ment. HoWever, in some patients one metastasis might regress while another
became larger, or new ones appeared.
All types of metastases were found to respond on occasions-skin nodules,
glands, lung and orbital metastases. Even pleural effusions dimished in amount,
and in 3 cases disappeared altogether with no treatment other than stilboestrol
dipropionate. It is also very interesting to note that in this series 13 patients
with bone metastases experienced relieffrom pain, while in 6, new bone formation
was demonstrated radiologically in osteolytic lesions. As this is not a finding
generally reported it may be useful to illustrate it with the following case:
Case No. 11,124, Mrs. E. B-.-This patient had a radical excision of the
right breast for carcinoma in 1928 when she was 43. She kept well until October,
1944, when she developed proptosis of the left eye. She was seen in the Radio-
therapy Department for the first time on 24.v. 45, when she was found to have
metastases in the left orbit, enlarged glands in the left side ofthe neck and diffuse
skeletal metastases. Fig. 6 shows the presence of osteolytic and osteoplastic
metastases in the pelvis on 24.v.45.
Stilboestrol dipropionate, 5 mg. twice a day, was prescribed, and by 2.viii.45
the proptosis had almost gone and the glands were no longer palpable. The
left eye appeared normal apart from slight ptosis of the upper lid. Fig. 7 shows
the radiographic appearance of the pelvis on 19.viii. 47. There had been con-
siderable improvement, and some of the metastases were difficult to detect.
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She continued to take stilboestrol dipropionate 5 mg. twice a day on alternate
months and remained well until December, 1948. She developed a tumour of
the cardiac end of the stomach and died on 27.viii.49. No post-mortem was
carried out, but this gastric tumour was probably metastatic in nature from the
carcinoma breast.
The following case illustrates the improvement which may take place in a
patient with a pleural effusion:
Ca8e No. 127/48, Mr8. J. L-.-This patient was treated by simplemastectomy
and X-ray therapy in January, 1948, for a Stage I carcinoma of the right breast
when she was aged 64. She remained well until November, 1948, when she
developed a metastasis in the opposite left breast, which was treated by simple
mastectomy and a palliative course of X-ray therapy.
On 19.i.50 she was found to have a right-sided pleural effusion (Fig. 8)
extending to the level of the third rib anteriorly. Treatment with stilboestrol
dipropionate 0*5 mg. thrice daily was commenced, and by 24.ii.50 there was
already considerable reduction in the pleural effusion (Fig. 9). Further reduc-
tion took place, until by June, 1950, the findings were within normal limits
(Fig. 10). She remained well until October, 1951, when she developed a febrile
illness, and an X-ray of her chest showed diffuse pulmonary metastases. Her
general condition is now deteriorating rapidly (December, 1951).
Dienoe,8trol.
The dosage of dienoestrol used was 1 mg. thrice daily in most cases. A few
received 5 mg. twice a day with no apparent advantage. The incidence of toxic
symptoms was minimal. Where a good response occurred the drug was con-
tinued indefinitely on alternate months.
The responses are shown in Table III.
TABLE III.--Results following Treatment with Dienoe8trol.
Total number of cases = 32.
Response. Numbers. Average Average Percentage survival/mths. age/yrs. premenopausal.
A. Good . . 2 (6-3%) . 44.0 . 07.0 . 0
B. Fair . . 3 (9.4%) . 9 0 . 60-5 . 0
C. None . . 23 (71.8%) . 17 6 . 59-0 . 0
D. Adverse . . 4 (12.5%) * 9.5 . 45 8 . 75
F,. Withdrawal . 0 .
Total . . 32 (100.0%)
The results shown in Table III are similar to those obtained in the group
treated with stilboestrol in respect of age distribution and relation to the meno-
pause. The numbers treated with dienoestrol are smaller, but a comparison of
Tables II and III would tend to suggest that dienoestrol is less effective than
stilboestrol.
Ofthose who did not respond well, one showed averygoodand 4 afairresponse
to stilboestrol.
One patient aged 64 who did not respond to dienoestrol showed a fair response
to testosterone, This would seema to suggest that a patient may respond to one
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type of hormone therapy and not to another, and it would be ofinterest to pursue
this point further.
Triphenylchlorethylene.
Only 6 cases were treated with triphenylchlorethylene. The dosage given
was 0 05 mg. twice a day. No case was made worse, but only one patient, aged
79, showed a slight response. Glands were reduced in size and lung metastases
did not advance for 4 months.
Ethinyl oestradliol.
The dosage ofethinyl oestradiol used in the majority of patients was 0 05 mg.
twice a day. Out of 38 patients treated, 12 experienced a considerable degree
of nausea and vomiting, especially in the first week of treatment. Some comn-
plained also of palpitation and vertigo. In 2, the dose had to be reduced to
0 05 mg. a day and, in other 2, it had to be reduced to 0 01 mg. twice a day.
This drug has only been used since December, 1948, and it is too soon to assess
survival rates.
TABLE IV.-Results following Treatment with Ethinyl Oestradiol.
Total number of cases = 38.
Response. Numbers. Average Numbers who were age/yrs. premenopausal.
A. Good . . . 2 (5.3%) . 65*0 . 0
B. Fair . . . 10 (26.3%) * 61-0 . 1
c. None . . . 24 (63.2%) . 61.5 . 1
D. Adverse . . 1 (2.6%) . 44-0 . 0
E. Withdrawal. . 1 (2.6%) . 53-0 . 1
Total . . 38 (100.0%)
Here again the results obtained are comparable with those shown in Tables
II and III.
The general impression gained from a study of Tables II, III and IV is that
stilboestrol dipropionate is the oestrogen preparation most likely to give beneficial
results. Dienoestrol, however, might be tried in a patient who is markedly
upset by stilboestrol.
Patients Treated by Testosterone.
A further series of 30 cases was treated with testosterone between July and
December, 1949.
The dose used was 50 mg. oftestosterone propionate daily, given intramuscu-
larly. Treatment was continued for 3 to 4 weeks, and if the patient's condition
showed some improvement, further treatment was given either by means of an
implant of 400 to 600 mg. of testosterone propionate into the abdominal wall
or by means of methyl testosterone. Methyl testosterone was given at a dose-
rate of 50 mg. a day on alternate months, and was administered in the form of
taiblets which were allowed to dissolve sublingually.
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The results are as shown in Table V.
TABLE V.-Results following Treatment with Testosterone Propionate.
Total number of cases - 30.
Response. Numbers. Averae age (years).
A. Good . . . 1 (3.3%) * 50
B. Fair . . . 7 (23-4%) . 48.2
c. None . . . 20 (66.7%) . 45 3
D. Adverse . . 1 (3 3%) . 43
E. Withdrawal . . 1 (3.30/) 52-1
Total . . . 30 (100.0%)
A remarkable improvement occurred in the general health of about 50 per
cent of the patients treated with testosterone, and this feeling of well-being may
not be undesirable, especially in the advanced stages of breast carcinoma. It
must be emphasised, however, that improvement in general condition was not
taken as a criterion ofresponse, and only patients in whom the tumour regressed
have been included among those showing favourable responses.
In this group of cases there seems to be no correlation between the type of
the response and the age of the patient. Favourable responses occurred in pre-
and post-mienopausal women, and also in some premenopausal patients who had
failed to respond to ovarian irradiation.
* The best results in this group occurred in patients with soft tissue metastases.
In one, enlarged glands disappeared completely, and in another 2 the primary
tumour showed a temporary regression. One patient who was comatose with
cerebral metastases improved sufficiently under treatment with testosterone to
attempt crossword puzzles. Subsequent post-mortem examination confirmed
the presence of large intracerebral metastatic deposits, which presumably had
regressed only temporarily under the influence oftestosterone.
In another patient a large pleural effusion did not cause anyfurther respiratory
embarrassment, and required aspiration only at increasingly longer intervals.
This patient is still alive 25 months after the commencement of treatment.
Only one patient experienced relief of pain from skeletal metastases while
receiving testosterone. Another patient with metastases in bone stated she
felt the pain easier when the drug was withdrawn. There was no radiological
evidence of repair occurring in bone metastases. The series, although small,
is in this respect at variance with the results so frequently reported in the
literature (Adair et al., 1949; Kaae, 1949; Report of the Council on Pharmacy
and Chemistry, 1949).
Only one patient could not tolerate the drug. She was a woman of 43 with
cerebral metastases, who developed very severe vomiting, and treatment had to
be discontinued after she had received 150 mg. Apart from this one patient no
one was upset by treatment. With the dosage used a few complained of nausea
at the beginning, but this passed off. Signs of masculinisation were seen in
most patients who received 2000 mg. or over. One patient developed a mild
acne, which disappeared when the testosterone was stopped. Premenopausal
patients developed amenorrhoea.
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Patients Treated by Ethisterone.
In order to make the investigation more complete it was felt that the effect
of ethisterone (androhydroxyprogesterone) should be tried.
Accordingly it was given to women (a) who had not yet reached the meno-
pause, as it was thought that they might show an adverse response to stilboestrol,
and (b) who had already shown an adverse response to stilboestrol. Actually,
only 7 were treated with this drug, but none showed any response.
Patients Treated by Pituitary Irradiation.
In October, 1949, an investigation was begun into the effects of irradiation
of the pituitary on the course of breast cancer. It was thought that the treat-
ment would bring about a complete cessation of all oestrogenic activity by sup-
pression of the gonadotrophic hormones. It was hoped that this would produce
better results than ovarian irradiation in younger women. Treatment was also
given to post-menopausal women to determine the effect.
Many of these patients had already failed to respond to other methods of
hormone therapy, and they were beyond the aid of all other forms oftreatment.
The pituitary was irradiated by two opposed fields, each 6 x 8 cm. placed in
the temporal region, and a dose of 3000r was delivered in 3 weeks to the region
ofthe sella turcica.
A series of 37 patients was treated between October, 1949, and October, 1950,
and the results are shown in Table VI.
As will be seen from Table VI, only 2 patients showed a good response. The
first patient was a woman of 51 whose periods had stopped 5 months before and
who had had no previous hormone treatment. A recurrent mass over the
sternum, 6 cm. in diameter, disappeared during the 3 weeks' treatment to the
EXPLANATION OF PLATES.
Fia. 1.-Case No. 26,101, Mrs. E. T- (15.ix.46).-Radiograph of pelvis before ovarian
irradiation showing extensive osteolytic metastatic involvement, particularly in region
of acetabula.
FIG. 2.-Same case as Fig. 1 (29.x.46).-Radiograph of pelvis following caesarean section
but before ovarian irradiation was carried out.
FIG. 3.-Same case as Fig. 1 (14.iv.47).-Radiograph ofpelvis 5 months after ovarian irradia-
tion showing new bone formation in acetabular regions and rings ofsclerosis round osteolytic
lesions in ilii.
FIG. 4.-Case No. 17,361, Mrs. C. S- (13.xi.45).-Radiograph of chest showing pleural
effusion on right side (before ovarian irradiation).
FIG. 5.-Same case as Fig. 4 (9.x. 46). Radiograph of chest 11 months after ovarian irradia-
tion showing considerable diminution in the amount ofthe pleural effusion with the presence
of a small fibrin body in the right costo-phrenic angle.
FIa. 6.-Case No. 11,124, Mrs. E. B- (24. v. 45).-Radiograph of pelvis showing widespread
osteolytic metastatic involvement (before administration of stilboestrol).
FIG. 7.-Same case as Fig. 6 (19.viii. 47).-Radiograph of pelvis 25 months after commence-
ment of treatment with stilboestrol. There has been considerable new bone formation
and restoration of the normal trabecular pattern.
FIG. 8.-Case No. 127/48, Mrs. J. L- (19. i. 50).-Radiograph of chest showing large pleural
effusion on right side (before treatment with stilboestrol).
FIG. 9.-Same case as Fig. 8 (24.ii. 50).-Radiograph of chest 1 month after commencement
of treatment with stilboestrol. There has been some diminution in amount of the pleural
effusion.
FIG. 10.-Same case as Fig. 8 (16.i.v50).-Radiograph of chest showing complete disap-
pearance ofpleural effusion.
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TABLE VI.-Results following Pituitary Irradiation.
Total number of cases = 37.
Response. Numbers. Average age (yrs).
A. Good . . . 2 (5.4%) . 48'S
B. Fair . . . 2 (5.4%) . 54-0
c. None . . . 33 (89.2%) . 52.9
Total . . . 37 (100.0%/)
pituitary in October, 1950. She remained well until August, 1951, when she
developed skeletal metastases, and her general condition is now very poor
(December, 1951).
The second good response occurred in a woman of 46. She had had an arti-
ficial menopause brought about by ovarian irradiation one year previously in an
attempt to control a local recurrence ofthe tumour. The recurrence had become
flatter for 3 months, but after that had spread again. Following pituitary
irradiation complete healing took place slowly, but new nodules appeared 10
months later.
Of the 2 women showing a fair response, the first was aged 46 and premeno-
pausal. She had a skin recurrence on the chest wall within the irradiated area
and was treated by pituitary irradiation in December, 1949. Slight regression
ofthe recurrence was noted for 3 months, but then the disease became widespread
and she died on 6.xii. 50. She had no periods following pituitary irradiation.
The other patient showing a fair response was aged 62 and had had a normal
menopause 7 years previously. In December, 1949, she developed oedema and
congestion ofthe face and neck due to pressure from enlarged mediastinal glands.
She was treated with pituitary, irradiation and her symptoms were relieved
during treatment. Unfortunately, one month later she developed other metas-
tases and her condition deteriorated. She died on 6.vi.50.
Among the 33 who did not respond the ages varied from 30 to 73. Twenty-
two had had ovarian irradiation previously, 6 had had stilboestrol and 2 testo-
sterone. None had shown any response to the other types ofhormone treatment.
It would seem from this that pituitary irradiation may be of value in the tylie
of case suitable for ovarian irradiation, or in cases where ovarian irradiation has
already been given with some good temporary effect.
There is no doubt that pituitary irradiation was the least well tolerated of all
forms of hormone therapy. Fourteen patients were very upset by the treatment
before the course was completed. It is possible that a modification of technique
and dosage would overcome some of these difficulties.
Of the 37 patients, 21 have died within one year, the average survival being
2 to 9 months after the commencement of treatment. Of the remaining 16,
only 5 are now able to be up and about.
Comparison with Cases Reported in the Literature.
The results which have been obtained agree with those already reported in
the literature as far as response in relation to age and the date of occurrence of
the menopause are concemed. There are, however, several interesting points
of difference, and some facts which have not been specially noted before,
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In the first place, although many series of cases have been published in the
past emphasising the value of ovarian irradiation in the treatment of premeno-
pausal women with advanced breast cancer (Foveau de Courmelles, 1926;
Ahlbom, 1930; Dresser, 1936; Martin, 1936; Smith, 1936), this particular
method appears to have been neglected in recent years in favour of testosterone.
The findings in Edinburgh suggest that it might with advantage be more exten-
sively used. It is very simply given as a single treatment in an X-ray depart-
ment, whereas treatment with testosterone is prolonged and expensive. It is
true that some women have troublesome side-effects such as flushings after
ovarian irradiation, but the results of prolonged testosterone administration,
hirsutes and other signs of masculinisation are not less distressing.
All writers are agreed on the value of the oestrogens in post-menopausal
women (Ellis et at., 1944; Haddow, Watkinson and Paterson, 1944; Taylor,
et al., 1948; "Report of the Council on Pharmacy and Chemistry," 1949;
Adair, et at., 1949; Walpole and Paterson, 1949). However, most reports state
that the best responses occur in patients with soft tissue metastases. It is
generally considered that oestrogens are oflittle value in the treatment ofskeletal
metastases, although Paterson (1944) reported relief from pain in such cases.
In the present series it was found that response was as likely to occur in bone
as elsewhere and, indeed, in 6 cases there was radiological proofofrepair occurring
in osteolytic metastases.
Conversely, our experience here with testosterone has been that almost all
the favourable responses have occurred in extra-skeletal metastases. No good
results were seen in bone lesions apart from relief of pain in 2 cases, although,
of course, the series was small, and treatment may not have been continued over
a long enough period. The reports in the literature on the efficacy oftestosterone
are very variable. All gradations of response have been reported. Farrow
(1944) noted a deleterious effect in female patients, Nathanson (1944) observed
no effect at all, and various later workers (Adair, 1947; Adair et al., 1949;
Kaae, 1949) reported a proportion ofgood responses in skeletal and extra-skeletal
metastases. All are agreed that testosterone may produce a beneficial effect
on the general health but this is a non-specific effect, and due partly to the
stimulating effect of the hormone on protein metabolism. It is, however, impor-
tant not to assess improvement in general health as an anti-carcinogenic effect.
With both oestrogen and androgen therapy some responses were noted here
after the drug was stopped-a withdrawal response. Farrow (1944) also noted
this occasionally in the metastases after withdrawal of either oestrogens or
androgens.
Consideration of the Mode of Action of Hormone Therapy.
WVhile hormone therapy is widely employed, the basis of treatment remains
largely empirical. The extension of our knowledge of the exact mode of action
would be of great interest, and might result in further advances in this form of
therapy.. The clinical results obtained, however, appear to be due to some
modification of the endocrine status of the patient.
Forexample, in a youngpatient who has not reached the menopause, oophorec-
tomy or ovarian irradiation causes a sudden withdrawal of the natural ovarian
hormones which influence the rate of growth of the cells of breast tissue whether
these cells are normal or malignant. The withdrawal ofthese naturally occurring
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oestrogenic substances results in an increased output of the gonadotrophic
hormones of the anterior pituitary which stimulate extra-gonadal sources of
oestrogenic activity such as the suprarenal cortex. Thus, as time passes, the
hormone balance of the body is partly restored and the beneficial effects of
castration wear off.
Pituitary irradiation must produce a similar effect to ovarian irradiation in
younger women, and bring about a cessation of all natural oestrogenic function.
The temporary effect obtained in the cases treated might, therefore, be due to
the level of dosage employed. At this stage of our knowledge, however, it is
doubtful ifit would be justifiable to use a higher dosage.
The administration of an artificial oestrogen again modifies the endocrine
status. The oestrogens may produce a direct effect on the breast cancer cells,
or the effect may be obtained indirectly through the anterior pituitary.
If the action is a direct one, the best results would be expected in older women.
Tn an older patient, for example a woman who is 5 or more years past the nmeno-
pause, there is little or no circulating oestradiol, and the addition of oestrogens
produces a change. After the passage of time, however, the body, and in
particular the breast cells, may become readjusted, and this might explain why
the good effect passes off.
The work of Zondek suggests that the oestrogens may have an indirect effect
through the anterior pituitary. Zondek (1936) found that the administration of
large doses of oestrin produced a chromophobe adenoma of the pituitary in male
rats,that is,inrats notnormallysubjecttotheactionof largeamountsofoestrogen.
Zondek (1947) also reports a case in which he gave large doses of oestradiol
benzoate to a woman of 216 with metastases from a carcinoma breast. No effect
was noted on the metastases, but after death her pituitary was found to weigh
710 g. as compared with a normal of 595 g. (the average for a nullipara of her
age according to Zondek). The increase in size of the pituitary was due to an
eosinophil adenoma.
Unless the production of an adenoma of the pituitaryr interferes with the
output ofother hormones the explanation is not very satisfactory in older patients.
In a premenopausal patient, a drug such as stilboestrol may cause inhibition
of the gonadotrophic hormones, so suppressing natural ovarian secretion, but
not bringing about a true castration. Castration could not be said to be complete
while an artificial oestrogenic substance is circulating in the blood. Conse-
quently, there is not the same profound change in the endocrine status and no
useful therapeutic effect is produced.
The question of the administration of testosterone might now be considered.
In a premenopausal patient this brings about an artificial menopause and, from
this point of view, testosterone might be expected to produce similar results to
ovarian irradiation or o6phorectomy. In addition to this, the administration
of testosterone must disturb the normal oestrogen-androgen ratio. Finally,
testosterone, like the oestrogens, causes inhibition ofthe gonadotrophic hormones
of the anterior pituitary (Moore and Price, 1932). It may, therefore, like the
oestrogens, produce an indirect effect on the breast cells by a disturbance of
pituitary function.
An explanation must now be sought for the failures. By any method so
far outlined the successes do not constitute more than about 30 per cent of the
total, It is possible that some patients have a more stable endocrine system,
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due to more rapid metabolic processes which quickly counteract the effects of
therapeutically induced changes. In this connection the liver must play an
important part, because the liver inactivates ovarian oestrogens (Golden and
Severinghaus, 1938). In hepatic cirrhosis there is an excess of free oestrogenic
substances in the blood. Westerfeld (1940) says tyrosinase, on incubation,
inactivates oestrone, oestradiol and diethylstilboestrol. Zondek and Sklow
(1942) believe the inactivation is caused by an enzyme-oestrinase-similar to
but not identical with tyrosinase. Jailer (1948) found that in mice fed on a
diet deficient in vitamin B1, the degradation mechanism of oestrogens in the
liver was impaired. It was not the vitamin B1 deficiency but the concomitant
inanition which was found to be the cause. In addition to the more common
causes of liver dysfunction, patients with carcinoma of the breast may have
metastatic involvement of the liver. How this would affect the response is not
known exactly, but it is perhaps significant that few patients with clinical evidence
of liver involvement showed any response to any of the methods of treatment
mentioned.
There may, however, be other factors modifying the response. The type of
tumour may play a part. Haddow, Watkinson and Paterson (1944) suggested
that the tumour called " carcinoma of the breast " might in reality comprise
several categories. Walpole and Paterson (1949) also made the same suggestion,
even going so far as to say that a tumour might produce an " anti-hormone"
or inhibitory factor antagonising the action of the oestrogen. They supported
this theory by their findings that, in general, patients who did not respond to
oestrogen therapy did not show such a complete degree of keratinisation of the
vaginal epithelium. If this change in the original epithelium is not obtained in a
post-menopausal woman, they suggested that some inhibitory factor was at
work. It seemed as though some substances were being produced, either in
the tumour or elsewhere, which were able to nullify oestrogenic activity.
A great deal offurther work will be necessary before the exact mode of action
can be determined.
SUMMARY AND CONCLUSIONS.
An extensive series of cases.of advanced breast carcinoma treated by hormone
therapy has been surveyed and the results obtained have been presented.
The findings suggest that, in premenopausal wonmen, the treatment of choice
is ovarian irradiation, which was found to produce beneficial results in 30 per
cent of patients in this category.
In women who are 5 or more years past the menopause, oestrogen therapy
would appear to be the most satisfactory form of treatment. The drug found to
be most generally useful was stilboestrol dipropionate 5 mg. twice a day on
alternate months.
While the results of treatment with testosterone have been disappointing, it
would appear to bethe most appropriate method oftreatment for post-menopausal
women who are not more than 5 years past the menopause, and it should be noted
that responses can be obtained where the metastases are confined to soft tissues.
Pituitary irradiation is no longer used routinely, because of the marked
systemic distuirbance produced. It may be of value in cases treated by ovarian
irradiation where the good effect has passed off.
It should be noted that both oestrogens and androgens promote water reten-
tion, and in a patient with a pleural effusion the dose has to be greatly reduced,
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Good results were noted with doses of stilboestrol dipropionate as low as 0 5 mg.
twice a day.
While ordinary methods of histological examination have failed to show any
correlation between histological type of the tumour and the response to hormone
therapy, it is possible that there are some differences in the cell which are not
detected by present methods.
Several suggestions have been offered to explain the mode ofaction, but much
work requires to be done on this aspect of the subject before further advances on
the therapeutic side are possible.
In conclusion, Iwouldliketo express mythanks to Professor Robert McWhirter
for his help and advice in the treatment of these cases and in the preparation of
this paper.
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